Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Broad Alliance Involves New Entities

Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.

businessman and businesswoman are exchanging document or contract
Multi-Vant Deal Finalized • Source: Shutterstock

Following their early September surprise announcement of a broad alliance, Sumitomo Dainippon Pharma Co. Ltd. (SDP) and Roivant Sciences Inc. have now finalized and fleshed out their $3bn deal under which the Japanese firm will acquire stakes in up to 11 "vant" companies.

On a strategic level, the transaction will provide SDP with much-needed late-stage candidates to tide it over its immediate post-Latuda...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.